 |
Actelion manufactures TracleerŪ, the first oral medicine approved by the FDA to treat patients with Pulmonary Arterial Hypertension (PAH). This chronic, life-threatening disorder affects approximately 100,000 people in the US and is often mis-diagnosed because its symptoms are similar to those of other conditions. Actelion chose Roska Direct Advertising to develop a direct-to-patient communication program based on the Agency's proven ability to motivate patient compliance and persistency across a variety of touchpoints.
|
|
|
|
